Analysts predict a 56% YoY growth for the company to break e...

Analysts predict a 56% YoY growth for the company to break even by 2026, an extremely optimistic outlook. Slower growth will delay profitability. The company's debt-free status, unusual for a loss-making biotech, lowers investment risk.